Noonan syndrome-associated biallelic LZTR1 mutations cause cardiac hypertrophy and vascular malformations in zebrafish.
LZTR1
Noonan syndrome
RAS/MAPK syndrome
hypertrophic cardiomyopathy
vascular malformation
Journal
Molecular genetics & genomic medicine
ISSN: 2324-9269
Titre abrégé: Mol Genet Genomic Med
Pays: United States
ID NLM: 101603758
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
10
03
2019
revised:
30
11
2019
accepted:
10
12
2019
pubmed:
29
12
2019
medline:
30
3
2021
entrez:
29
12
2019
Statut:
ppublish
Résumé
Variants in the LZTR1 (leucine-zipper-like transcription regulator 1) gene (OMIM #600574) have been reported in recessive Noonan syndrome patients. In vivo evidence from animal models to support its causative role is lacking. By CRISPR-Cas9 genome editing, we generated lztr1-mutated zebrafish (Danio rerio). Analyses of histopathology and downstream signaling were performed to investigate the pathogenesis of cardiac and extracardiac abnormalities in Noonan syndrome. A frameshift deletion allele was created in the zebrafish lztr1. Crosses of heterozygotes obtained homozygous lztr1 null mutants that modeled LZTR1 loss-of-function. Histological analyses of the model revealed ventricular hypertrophy, the deleterious signature of Noonan syndrome-associated cardiomyopathy. Further, assessment for extracardiac abnormalities documented multiple vascular malformations, resembling human vascular pathology caused by RAS/MAPK activation. Due to spatiotemporal regulation of LZTR1, its downstream function was not fully elucidated from western blots of adult tissue. Our novel zebrafish model phenocopied human recessive Noonan syndrome and supported the loss-of-function mechanism of disease-causing LZTR1 variants. The discovery of vascular malformations in mutants calls for the clinical follow-up of patients to monitor for its emergence. The model will serve as a novel platform for investigating the pathophysiology linking RAS/MAPK signaling to cardiac and vascular pathology.
Sections du résumé
BACKGROUND
Variants in the LZTR1 (leucine-zipper-like transcription regulator 1) gene (OMIM #600574) have been reported in recessive Noonan syndrome patients. In vivo evidence from animal models to support its causative role is lacking.
METHODS
By CRISPR-Cas9 genome editing, we generated lztr1-mutated zebrafish (Danio rerio). Analyses of histopathology and downstream signaling were performed to investigate the pathogenesis of cardiac and extracardiac abnormalities in Noonan syndrome.
RESULTS
A frameshift deletion allele was created in the zebrafish lztr1. Crosses of heterozygotes obtained homozygous lztr1 null mutants that modeled LZTR1 loss-of-function. Histological analyses of the model revealed ventricular hypertrophy, the deleterious signature of Noonan syndrome-associated cardiomyopathy. Further, assessment for extracardiac abnormalities documented multiple vascular malformations, resembling human vascular pathology caused by RAS/MAPK activation. Due to spatiotemporal regulation of LZTR1, its downstream function was not fully elucidated from western blots of adult tissue.
CONCLUSION
Our novel zebrafish model phenocopied human recessive Noonan syndrome and supported the loss-of-function mechanism of disease-causing LZTR1 variants. The discovery of vascular malformations in mutants calls for the clinical follow-up of patients to monitor for its emergence. The model will serve as a novel platform for investigating the pathophysiology linking RAS/MAPK signaling to cardiac and vascular pathology.
Identifiants
pubmed: 31883238
doi: 10.1002/mgg3.1107
pmc: PMC7057116
doi:
Substances chimiques
Zebrafish Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1107Informations de copyright
© 2019 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals, Inc.
Références
Proc Natl Acad Sci U S A. 2013 Aug 20;110(34):13904-9
pubmed: 23918387
Mol Genet Genomic Med. 2020 Mar;8(3):e1107
pubmed: 31883238
Nat Commun. 2018 Nov 2;9(1):4603
pubmed: 30389937
J Biol Chem. 2006 Feb 24;281(8):5065-71
pubmed: 16356934
Genet Med. 2018 Oct;20(10):1175-1185
pubmed: 29469822
Nat Protoc. 2013 Apr;8(4):800-9
pubmed: 23538883
Sci Rep. 2014 Sep 19;4:6420
pubmed: 25236476
J Hum Genet. 2016 Jan;61(1):33-9
pubmed: 26446362
Genet Med. 2019 Jan;21(1):260
pubmed: 29959388
J Clin Invest. 2007 Aug;117(8):2123-32
pubmed: 17641779
Science. 2018 Dec 7;362(6419):1177-1182
pubmed: 30442762
J Clin Invest. 2018 Apr 2;128(4):1496-1508
pubmed: 29461977
Genet Med. 2015 May;17(5):405-24
pubmed: 25741868
Dis Model Mech. 2009 Jan-Feb;2(1-2):56-67
pubmed: 19132118
Nat Med. 2004 Aug;10(8):849-57
pubmed: 15273746
Hum Genet. 2019 Jan;138(1):21-35
pubmed: 30368668